## **Patent Application** Attorney Docket No.PC10343C

(Signature of person mailing) Madeline Deveran (Typed or printed name of person) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NRE APPLICATION OF:

Graham Maw, et al.

APPLICATION NO.:

10/686,349

Examiner: To Be Assigned

FILING DATE:

October 15, 2003

Group Art Unit: 1617

Compounds for the Treatment of Female Sexual: TITLE:

Dysfunction

Mail Stop Amendment

Hon. Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s). The references for this application can be found in the parent case U.S. Non-Provisional Application No. 09/708,392.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: '

Pfizer Inc.

Patent Department, MS 8260-1611

Eastern Point Road

Groton, Connecticut 06340

(860) 715-4288

Martha G. Munchhof

Attorney for Applicant(s)

Reg. No. 47,811

INFORMATION DISCLOSURE CITATION ATTY. DOCKET NO. PC10343C SERIAL NO.10,686,349

APPLICANT Graham Nigel Maw, et al.

**GROUP** FILING DATE October 15, 2003 1617 **U.S. PATENT DOCUMENTS** EXAMINER INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING DATE IF APPROPRIATE US 9 6-7-88 Kruse, Lawrence 514 392 US 5 3 4 6 9 0 1 9-13-94 Bell, et al 514 258 Equivalent to RU2114114 7 258 US 6 5 5-22-01 Bell, et al 514 7 3 4 2 Maw, et al 514 263.1 US 6 7 3 4 6 5-11-04 **FOREIGN PATENT DOCUMENTS** COUNTRY SUBCLASS TRANSLATION DOCUMENT NUMBER DATE CLASS NO WO 9 8 5 2 8 0 11-26-98 International C07C 21/00 wo 9 8 2-26-98 International A61K 31/34 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Beavo, et al, TIPS Reviews, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors", Vol. 11, pp. 150-155, (1990) Brandenburg, et al., The Journal of Neuroscience, "Identification Of Endogenous Sympathetic Neuron Pituitary Adenylate Cyclase-Activating Polypeptide (PACCAP): Depolarization Regulates Production And Secretion Through Induction Of Multiple Propeptide Transcripts", Vol. 17(11) pp. 4045-4055 (1997) May, et al., The Journal of Neuroscience, "Differential Regulation of sympathetic Neuron Neuropeptide Y and Catecholamine Content and Secretion", Vol. 15(6), pp. 4580-4591, (1995) May, et al., <u>Journal of Neurochemistry</u>, "Pituitary Adenylate Cyclase-Activitating Polypeptide (PACAP) Regulation Of Sympathetic Neuron Neuropeptide Y And Catecholamine Expression", Vol. 65, pp. 978-987 (1995) Zusman, et al., American Journal of Cardiology, "Overall Cardiovascular Profile Of Sildenafil Citrate", Vol. 83, pp. 35C-44C, (1999) US Application #09.708,392, filed November 8, 2000, Maw et al, Patent US6734186 filed May 11, 2004 US Application #09/895,367, filed June 29, 2001, Naylor, et al U.S. 2003/0027824, filed February 6, 2003; Ellis, et al., 514/234.5 equivalent to RU2130776 U.S. 2003/0067945, filed April 8, 2004; Niewohner, et al., ., 514/234 equivalent to WO99/24433 **EXAMINER** DATE CONSIDERED

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE